share_log

Needham Maintains Buy on AtriCure, Lowers Price Target to $44

Needham Maintains Buy on AtriCure, Lowers Price Target to $44

Needham维持对AtriCure的买入,将目标股价下调至44美元
Benzinga ·  01/04 06:27

Needham analyst Mike Matson maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $49 to $44.

尼德姆分析师迈克·马特森维持AtriCure(纳斯达克股票代码:ATRC)的买入并将目标股价从49美元下调至44美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发